Sanofi Spotlights Nirsevimab In RSV, Further Dupixent Development
Oncology Sales Growing
Sanofi executives are upbeat about the potential advantages of its monoclonal antibody-based approach to the prevention of RSV infections in infants, the future growth of the company’s Dupixent franchise, and the progress of its novel anticancers.
You may also be interested in...
Janssen And Sanofi Keep Mum On EU Fast-Track Request Outcomes
Teclistamab and nirsevimab may or not be fast-tracked when their sponsors – Janssen-Cilag and Sanofi, respectively – file for pan-EU approval. In the meantime, a total of seven filings are currently benefiting from the accelerated assessment mechanism at the European Medicines Agency.
Sanofi Adds To Vaccine Pipeline With Origimm Acquisition
As well as buying Origimm, the French giant will also apply its mRNA vaccine platform, acquired through the recent $3.2bn acquisition of Translate Bio, to discover and develop other acne vaccines, aided by the Vienna-headquartered firm's know-how in the field.
AstraZeneca Unveils New Vaccines Division But Strategy Remains Unclear
AstraZeneca’s creation of a new division does not mean it sees a long-term future for its COVID-19 vaccine.